News

Regulatory Milestone Underscores Urgency and Promise of First-in-Class Mitochondrial Cell TherapyHaifa, ISRAEL, June 30, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”) ...
Minovia Therapeutics said Monday that the Food and Drug Administration granted fast-track and rare-pediatric-disease designations to its lead investigational compound. The drug, MNV-201, is in Phase 2 ...
NOVATO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that it has ...
The PHOENIX study is a 24-month, randomized, double-masked, placebo-controlled, multicenter, pivotal Phase 3 trial. The study is ongoing across sites in the United States, the United Kingdom, France, ...
Neurofibromatosis Type 2 Market Insight, Epidemiology And Market Forecast - 2034The Neurofibromatosis Type 2 treatment market is experiencin ...
Here are the latest updates for six hospital systems across the Northwest Austin area. 1. Ascension Seton Northwest Hospital ...
The Senate Parliamentarian reversed course on a small provision in the One Big Beautiful Bill Act that could boost cures for ...
Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?
Prof. Moran Hausman-Kedem, a pediatric neurologist involved in the research, emphasized the clinical value of the model: “For rare diseases where patient populations are too small for large-scale ...
Nearly 150 new Florida laws went into effect on July 1 after Gov. Ron DeSantis signed 11 more the day before. Here is what ...
Explosion in the tick pop­u­lation draws attention to rare Lyme disease symptoms in children BY Erin Billups - National Health Reporter Nationwide UPDATED 7:35 PM ET Jun. 21, 2021 ...